A Case of Dulaglutide-Induced Acute Interstitial Nephritis After Many Years of Treatment With an Alternate GLP-1 Receptor Agonist

Case Studies| October 14 2022 A Case of Dulaglutide-Induced Acute Interstitial Nephritis After Many Years of Treatment With an Alternate GLP-1 Receptor Agonist Muralikrishna Gangadharan Komala 0000-0003-0534-0584 ; Muralikrishna Gangadharan Komala 1Norwest Hospital, New South Wales, Australia2Sydney University, New South Wales, Australia3Nepean Hospital, New South Wales, Australia Corresponding author: Muralikrishna Gangadharan Komala, murali.komala@sydney.edu.au Search for other works by this author on: This Site PubMed Google Scholar Jasveen Renthawa Jasveen Renthawa 4Westmead Hospital, New South Wales, Australia Search for other works by this author on: This Site PubMed Google Scholar Corresponding author: Muralikrishna Gangadharan Komala, murali.komala@sydney.edu.au Clin Diabetes 2022;40(4):508–510 https://doi.org/10.2337/cd21-0142 PubMed: 36385974 Views Icon Views Article contents Figures & tables Video Audio Supplementary Data Peer Review Share Icon Share Facebook Twitter LinkedIn Email Cite Icon Cite Get Permissions Citation Muralikrishna Gangadharan Komala, Jasveen Renthawa; A Case of Dulaglutide-Induced Acute Interstitial Nephritis After Many Years of Treatment With an Alternate GLP-1 Receptor Agonist. Clin Diabetes 14 October 2022; 40 (4): 508–510. https://doi.org/10.2337/cd21-0142 Download citation file: Ris (Zotero) Reference Manager EasyBib Bookends Mendeley Papers EndNote RefWorks BibTex toolbar search Search Dropdown Menu toolbar search search input Search input auto suggest filter your search All ContentAll JournalsClinical Diabetes Search Advanced Search The newer antidiabetic medications have revolutionized management of diabetes. These include the sodium–glucose cotransporter 2 (SGLT2) inhibitors and the long-acting glucagon-like peptide 1 (GLP-1) receptor agonists. These two classes of drugs provide additional cardiovascular and renal benefits beyond glycemic control, making them attractive choices in this new era of diabetes therapy. The benefits of drugs in these two classes include weight loss and improved blood pressure control. They have a limited number of adverse effects, including urinary tract infections in patients on SGLT2 inhibitors and gastrointestinal symptoms in those receiving long-acting GLP-1 receptor agonists. Although the newer GLP-1 receptor agonists have not been noted to have any significant renal adverse effects, there are a few reported instances of renal injury induced by the GLP-1 receptor agonist semaglutide (1). However, there is only one known case report of dulaglutide-induced kidney injury (2). However, this case did not... You do not currently have access to this content.